Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Bionomics stock

BNO.AX
AU000000BNO5
936199

Price

0.01
Today +/-
+0
Today %
+0 %

Bionomics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Bionomics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bionomics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bionomics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bionomics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bionomics Stock Price History

DateBionomics Price
8/28/20230.01 undefined
8/25/20230.01 undefined

Bionomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bionomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bionomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bionomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bionomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bionomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bionomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bionomics’s growth potential.

Bionomics Revenue, EBIT and net profit per share

DateBionomics RevenueBionomics EBITBionomics Net Income
2026e34.3 M undefined-37.95 M undefined-28.19 M undefined
2025e5.14 M undefined-58.58 M undefined-436.87 M undefined
2024e8.79 M undefined-32.01 M undefined-252.92 M undefined
2023e5.14 M undefined-26.66 M undefined-35.6 M undefined
2022263,630 undefined-22.27 M undefined-21.76 M undefined
20210 undefined-8.68 M undefined-8.7 M undefined
202046,660 undefined-4.1 M undefined-7.12 M undefined
2019906,120 undefined-8.3 M undefined-10.36 M undefined
20183.95 M undefined-20.84 M undefined-25.09 M undefined
201718.61 M undefined-5.46 M undefined-6.75 M undefined
20168.14 M undefined-17.79 M undefined-16.59 M undefined
20156.83 M undefined-26.13 M undefined-16.95 M undefined
201419.92 M undefined-3.06 M undefined3.21 M undefined
20133.72 M undefined-17.99 M undefined-10 M undefined
20126.83 M undefined-6.36 M undefined-3.14 M undefined
20114.07 M undefined-9.05 M undefined-9.36 M undefined
20103.85 M undefined-8 M undefined-8.21 M undefined
20094.3 M undefined-6.93 M undefined-6.86 M undefined
20087.08 M undefined-4.83 M undefined-4.78 M undefined
20073.43 M undefined-7.59 M undefined-5.45 M undefined
20064.57 M undefined-5.23 M undefined-5.4 M undefined
20053.17 M undefined-4.31 M undefined-4.63 M undefined
20041.98 M undefined-3.26 M undefined-3.58 M undefined
20031.61 M undefined-4.24 M undefined-4.54 M undefined

Bionomics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
002113437434631968183000058534
----50.00-200.0033.33-25.00133.33-42.86-25.0033.3350.00-50.00533.33-68.4233.33125.00-83.33-----60.00-37.50580.00
---------------------------
000000000000000000000000000
-1-3-3-4-3-4-5-5-4-6-8-9-3-103-16-16-6-25-10-7-8-21-35-252-436-28
-200.00-33.33-25.0033.3325.00--20.0050.0033.3312.50-66.67233.33-130.00-633.33--62.50316.67-60.00-30.0014.29162.5066.67620.0073.02-93.58
0.010.030.040.040.060.080.160.180.230.240.30.320.350.370.420.420.530.550.550.60.590.781.350000
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Bionomics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bionomics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                             
4.549.838.626.078.79.014.7312.826.284.7612.6116.0517.3722.458.7526.5645.4542.8724.9313.994.5828.9433.56
0.060.030.070.030.060.010.250.662.10.640.590.573.347.4328.10.391.240.830.580.810.020.20.04
0.080.080.10.030.130.140.030.270.250.140.287.970.540.310.48.789.769.078.427.912.960.946.74
000003050100801201104014010080409.89438.86425.74490.09664.54000
0.010.020.040.070.080.250.110.10.140.230.30.250.350.422.181.741.191.281.51.760.770.861.46
4.699.968.836.28.979.445.1713.958.855.8913.8924.8821.7430.7139.5137.8858.0954.4835.9225.138.3330.9341.81
0.440.726.916.315.985.655.658.638.628.387.910.30.770.840.833.452.842.622.742.511.050.870.67
000000000000000000384384436.17119119
00000000000000000000000
0.190.140.10.060.0206.736.115.695.314.563.973.3716.915.2316.9316.0614.3313.5512.8711.779.959.84
000001.962.182.135.155.155.155.155.155.159.4910.4912.4412.2612.4712.7612.8712.412.87
000000000000700038438438400000
0.630.867.016.3767.6114.5616.8719.4618.8417.629.429.3622.8925.5531.2531.7229.629.1528.5326.1323.3423.5
5.3210.8215.8412.5714.9717.0519.7330.8228.3124.7331.5134.331.153.665.0669.1389.8184.0865.0753.6634.4654.2665.31
                                             
7.415.8119.120.3726.1632.7938.0452.8356.159.9775.1187.6987.83111.31111.72111.99134.39134.54135.21144.94148.16190.19217.7
00000000000000000000000
-2.34-5.62-9.11-13.65-17.22-22.11-27.09-30.14-37.55-44.48-51.67-58.44-61.29-71.15-67.8-84.23-95.4-99.14-123.82-134.7-141.76-147.71-166.97
0000000000-0.48-0.55-0.651.250.894.215.175.065.566.256.295.126.19
000000002.983.212.51000000000000
5.0610.199.996.728.9410.6810.9522.6921.5318.725.4728.725.8941.4144.8131.9744.1640.4516.9616.512.6847.656.91
0.070.150.350.350.521.011.082.121.731.141.381.361.993.272.663.932.631.93.611.241.261.031.56
0.080.340.190.260.180.260.470.320.140.380.550.520.841.012.564.114.813.373.763.881.061.161.64
0.020.10.180.120.20.410.730.630.610.740.670.780.911.123.270.21.210.130.220.23000
00000000000000000000000
000.130.510.510.360.410.540.570.530.632.830.730.680.795.462.738.55.78.455.950.170.16
0.170.590.851.241.412.042.693.613.052.793.235.494.476.089.2813.7111.3913.8913.2813.88.272.363.36
004.964.584.584.293.973.883.543.172.690.010.440.40.519.3218.4410.0115.749.856.280.690.53
0000002.020.510000004.345.635.134.7732.942.21.841.8
0.070.050.050.050.050.050.10.120.20.070.120.120.295.726.128.5110.714.9516.0810.575.021.772.71
0.070.055.014.634.634.346.094.513.743.242.810.130.736.1210.9723.4634.2629.7334.8223.3613.514.315.04
0.240.645.865.876.046.388.788.126.796.036.045.625.212.220.2537.1745.6543.6248.1137.1621.786.678.4
5.310.8315.8512.5914.9817.0619.7330.8128.3224.7331.5134.3231.0953.6165.0669.1389.8184.0865.0753.6634.4654.2665.31
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Bionomics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bionomics's financial health and stability.

Assets

Bionomics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bionomics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bionomics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bionomics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
00000000000000000000000
00000000000000000000000
00000000000000000000000
00211222300004779986720
00000000000000000000000
0000000000000000-1-1-1-1-100
00000000000000000000000
-1-2-2-3-2-3-3-6-6-4-7-8-4-10-124-15-1-20-15-3-7-21
00-100-200000000000000000
00-100-200000060001000000
00000000000070001100000
00000000000000000000000
000000000000-100124-22-5-8-110
7831660140314120150028001034332
683156014031412-11501233-224-53126
-----------------------5.00
00000000000000000000000
21-6-7-1-5-100-16-60-5-3-9-3114-4-11-44-31-1914-16
-1.95-3.04-4.45-3.77-3.19-5.86-3.93-6.44-7-5.1-7.15-9.06-4.66-10.22-13.134.09-15.56-1.69-20.94-15.68-3.91-7.54-21.76
00000000000000000000000

Bionomics stock margins

The Bionomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bionomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bionomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bionomics's sales revenue. A higher gross margin percentage indicates that the Bionomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bionomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bionomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bionomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bionomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bionomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bionomics Margin History

Bionomics Gross marginBionomics Profit marginBionomics EBIT marginBionomics Profit margin
2026e0 %-110.64 %-82.18 %
2025e0 %-1,139.61 %-8,499.4 %
2024e0 %-364.33 %-2,878.39 %
2023e0 %-518.75 %-692.65 %
20220 %-8,447.9 %-8,253.75 %
20210 %0 %0 %
20200 %-8,784.83 %-15,255.66 %
20190 %-915.65 %-1,143.51 %
20180 %-527.05 %-634.44 %
20170 %-29.35 %-36.28 %
20160 %-218.43 %-203.76 %
20150 %-382.7 %-248.26 %
20140 %-15.36 %16.11 %
20130 %-483.6 %-268.82 %
20120 %-93.12 %-45.97 %
20110 %-222.36 %-229.98 %
20100 %-207.79 %-213.25 %
20090 %-161.16 %-159.53 %
20080 %-68.22 %-67.51 %
20070 %-221.28 %-158.89 %
20060 %-114.44 %-118.16 %
20050 %-135.96 %-146.06 %
20040 %-164.65 %-180.81 %
20030 %-263.35 %-281.99 %

Bionomics Stock Sales Revenue, EBIT, Earnings per Share

The Bionomics earnings per share therefore indicates how much revenue Bionomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bionomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bionomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bionomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bionomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bionomics Revenue, EBIT and net profit per share

DateBionomics Sales per ShareBionomics EBIT per shareBionomics Earnings per Share
2026e0.02 undefined0 undefined-0.02 undefined
2025e0 undefined0 undefined-0.3 undefined
2024e0.01 undefined0 undefined-0.17 undefined
2023e0 undefined0 undefined-0.02 undefined
20220 undefined-0.02 undefined-0.02 undefined
20210 undefined-0.01 undefined-0.01 undefined
20200 undefined-0.01 undefined-0.01 undefined
20190 undefined-0.01 undefined-0.02 undefined
20180.01 undefined-0.04 undefined-0.05 undefined
20170.03 undefined-0.01 undefined-0.01 undefined
20160.02 undefined-0.03 undefined-0.03 undefined
20150.02 undefined-0.06 undefined-0.04 undefined
20140.05 undefined-0.01 undefined0.01 undefined
20130.01 undefined-0.05 undefined-0.03 undefined
20120.02 undefined-0.02 undefined-0.01 undefined
20110.01 undefined-0.03 undefined-0.03 undefined
20100.01 undefined-0.03 undefined-0.03 undefined
20090.02 undefined-0.03 undefined-0.03 undefined
20080.03 undefined-0.02 undefined-0.02 undefined
20070.02 undefined-0.04 undefined-0.03 undefined
20060.03 undefined-0.03 undefined-0.03 undefined
20050.04 undefined-0.05 undefined-0.06 undefined
20040.03 undefined-0.06 undefined-0.06 undefined
20030.04 undefined-0.1 undefined-0.11 undefined

Bionomics business model

Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of novel therapeutics for the treatment of diseases of the central nervous system and cancer. The company is headquartered in Adelaide, South Australia, and has offices and research facilities in the United States and France. Bionomics was founded in 1998 by Dr. Deborah Rathjen, an experienced biotechnology manager and scientist. The company started as a spin-off from Flinders University in Adelaide, focusing initially on the discovery and development of drug candidates based on novel peptides. In 2002, Bionomics went public, gaining access to capital to expand its research activities and adjust its business strategy. Bionomics operates an integrated pharmaceutical model, ranging from the discovery and optimization of novel therapeutic targets and drugs to clinical development and market launch of pharmaceuticals. The company develops innovative technologies, including the MultiCore platform, to develop peptide-based drugs. Bionomics has two main divisions: CNS therapy and cancer therapy. The CNS therapy division focuses on the development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, anxiety disorders, neuropathic pain, spinal cord injuries, and other disorders. Bionomics is currently conducting clinical trials to evaluate the effectiveness of its leading drug candidates BN311 and BNO69 in the treatment of depression and anxiety disorders. Bionomics' cancer therapy division focuses on the discovery and development of drug candidates for the treatment of cancer. The company has identified a number of leading preclinical drug candidates based on novel targets, showing promising results in the treatment of breast, lung, ovarian, liver cancer, and other types of cancer. Bionomics has a range of products in development or in clinical stages. The company's leading product is BN311, a drug candidate for the treatment of depression based on Bionomics' MultiCore technology. BN311 has shown efficacy in preclinical studies in the treatment of depression and anxiety disorders and is currently being tested in a phase II clinical trial. BNO69 is another drug candidate from Bionomics based on the same technology. The candidate has been developed for the treatment of anxiety disorders and shows great promise. It has proven effective in preclinical studies and has the potential to revolutionize the treatment of anxiety disorders. The company is also developing drug candidates for the treatment of cancer, including BNC101, BNC105, BNC211, and BNC375. All of these drug candidates are based on novel targets and have shown promising results in preclinical studies. BNC375, a cancer immunotherapy, shows particularly promising results, and the company plans to conduct a phase I clinical trial to evaluate the efficacy of the drug in treating patients with advanced cancer. Overall, Bionomics Ltd is an emerging biopharmaceutical company specializing in the development of new and promising therapeutics for the treatment of diseases of the central nervous system and cancer. Bionomics has developed an integrated pharmaceutical model that supports innovation from discovery to commercialization and has a promising pipeline of drug candidates for the next generation of medications. Bionomics is one of the most popular companies on Eulerpool.com.

Bionomics SWOT Analysis

Strengths

Bionomics Ltd possesses several strengths that contribute to its success and competitiveness in the market. These include:

  • Strong Intellectual Property Portfolio: Bionomics has a robust portfolio of patents and intellectual property rights, providing a competitive advantage in the development and commercialization of innovative therapies.
  • Expertise in Drug Discovery: The company has a talented team of researchers and scientists with deep expertise in drug discovery, facilitating the development of novel and effective therapies.
  • Strategic Partnerships: Bionomics has established strategic collaborations with leading pharmaceutical companies, enabling access to additional resources, expertise, and funding.
  • Diversified Pipeline: The company's pipeline comprises a range of promising therapeutic candidates targeting various diseases, reducing reliance on a single product.
  • Global Presence: Bionomics has expanded its operations and presence internationally, allowing access to a larger patient population and diverse markets.

Weaknesses

Despite its strengths, Bionomics also faces certain weaknesses that need to be addressed in order to maintain its position in the market:

  • Heavy Reliance on Funding: The company heavily relies on external funding for its research and development activities, making it vulnerable to fluctuations in funding availability.
  • Limited Product Diversity: Bionomics currently has a limited number of products in its commercial portfolio, which exposes the company to risks associated with product failures or market shifts.
  • Competitive Market: The biopharmaceutical industry is highly competitive, with numerous players vying for market share. Bionomics needs to differentiate itself effectively to stand out among its rivals.

Opportunities

Bionomics can leverage various opportunities to further expand its business and enhance its market position:

  • Growing Demand for Personalized Medicine: The increasing focus on personalized medicine presents an opportunity for Bionomics to develop targeted therapies tailored to individual patient needs.
  • Advances in Technology: Rapid advancements in technology, such as genomics and bioinformatics, provide new tools and insights for drug discovery, which Bionomics can leverage to accelerate the development process.
  • Emerging Markets: Expansion into emerging markets offers the potential for increased sales and market exposure. Bionomics can explore partnerships or establish subsidiaries in these regions to tap into their growing patient populations.

Threats

Bionomics faces certain threats that may impact its growth and sustainability:

  • Regulatory Challenges: Stringent regulations and approval processes in the pharmaceutical industry can pose delays and additional costs for Bionomics' drug candidates.
  • Market Volatility: Fluctuations in market conditions, including economic downturns and changes in healthcare policies, can affect the company's financial performance and investor confidence.
  • Intellectual Property Risks: The risk of intellectual property infringement or challenges from competitors can undermine Bionomics' market exclusivity and competitive advantage.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bionomics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bionomics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bionomics shares outstanding

The number of shares was Bionomics in 2024 — This indicates how many shares 1.353 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bionomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bionomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bionomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bionomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Bionomics.

Bionomics shareholders

%
Name
Stocks
Change
Date
17.73972 % Apeiron Investment Group Ltd260,550,387011/1/2022
11.58067 % BVF Partners L.P.170,089,885011/21/2022
2.20664 % US Register Control32,409,786-1,798,6309/5/2022
1.22525 % HUB24 Ltd.17,995,68717,995,6879/5/2022
0.61972 % Camm (Jason Howard David)9,102,13209/5/2022
0.60488 % L & M Group Ltd.8,884,08509/5/2022
0.46503 % Forward Vision VII L.P. Series 26,830,075-12,548,4269/5/2022
0.37447 % Potter (Mark Richard)5,500,0005,500,0009/5/2022
0.34043 % Charmed5 Pty. Ltd.5,000,0005,000,0009/5/2022
0.34043 % Qualvest Pty. Ltd.5,000,0001,000,0009/5/2022
1
2
3

Most common questions regarding Bionomics

What values and corporate philosophy does Bionomics represent?

Bionomics Ltd is a biotechnology company that represents core values of innovation, scientific excellence, and dedication to improving healthcare outcomes. With a strong corporate philosophy, Bionomics strives to create novel and differentiated therapeutics to address unmet medical needs. Their commitment to cutting-edge research and development is evident in their focus on discovering and advancing drug candidates in areas like cancer, central nervous system disorders, and inflammatory diseases. Bionomics Ltd aims to deliver value to patients, healthcare providers, and investors through their robust pipeline and strategic collaborations. As a leading biotech firm, Bionomics maintains a steadfast commitment to improving lives through pioneering scientific advancements.

In which countries and regions is Bionomics primarily present?

Bionomics Ltd is primarily present in two countries, Australia and the United States. The company is headquartered in Adelaide, South Australia, and has research and development facilities in San Diego, California. With a focus on developing innovative therapeutics for various diseases, Bionomics Ltd has established a strong presence in these regions. The company's presence in these countries allows it to leverage the scientific and business expertise available in both Australia and the United States, contributing to its mission of discovering and advancing novel drugs.

What significant milestones has the company Bionomics achieved?

Bionomics Ltd has achieved several significant milestones. The company successfully developed BNC105, a promising anti-cancer drug candidate. In addition, Bionomics has entered into strategic partnerships and collaborations with notable pharmaceutical companies including Merck & Co. and Ironwood Pharmaceuticals. These partnerships have paved the way for the advancement of their drug pipeline. Furthermore, Bionomics has made progress in clinical trials, demonstrating positive results in various studies. With a strong focus on innovation and research, Bionomics Ltd continues to make strides in the pharmaceutical industry, driving potential growth and success.

What is the history and background of the company Bionomics?

Bionomics Ltd is a biotechnology company based in Australia. Founded in 1999, it specializes in the discovery and development of innovative therapeutics for various diseases. With a strong focus on neuroscience and cancer, Bionomics has built a diverse pipeline of potential treatments. The company has a rich history of collaboration with pharmaceutical giants, such as Merck & Co. and Ironwood Pharmaceuticals, which further strengthens its research capabilities. Bionomics is known for its expertise in discovering novel drug targets and utilizing its proprietary drug discovery platform, known as MultiCore. Over the years, Bionomics has cultivated a reputation for delivering cutting-edge solutions in the field of biotechnology.

Who are the main competitors of Bionomics in the market?

Bionomics Ltd faces strong competition in the market from pharmaceutical companies such as Novartis, Pfizer, and GlaxoSmithKline. These industry giants also focus on developing innovative drug therapies and discovering potential treatments. Bionomics Ltd's main competitors continually invest in research and development, similar to Bionomics Ltd, to stay competitive in the healthcare industry. As a biotech company, Bionomics Ltd aims to deliver groundbreaking solutions that cater to unmet medical needs. With these key players in the market, Bionomics Ltd strives to differentiate itself through its unique approaches and effective drug development strategies.

In which industries is Bionomics primarily active?

Bionomics Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Bionomics?

Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of innovative drug candidates. The company's business model focuses on discovering and advancing novel therapeutics in the areas of central nervous system disorders and cancer. Bionomics utilizes proprietary platform technologies to identify and target specific molecular pathways involved in disease processes. By employing a combination of preclinical and clinical research, Bionomics aims to bring potential treatments to market, addressing unmet medical needs. With a strong focus on research and development, Bionomics collaborates with strategic partners and aims to deliver value to patients, healthcare providers, and investors alike.

What is the P/E ratio of Bionomics 2025?

The Bionomics P/E ratio is -0.03.

What is the P/S ratio of Bionomics 2025?

The Bionomics P/S ratio is 2.63.

What is the Quality Investing of Bionomics?

The Quality Investing for Bionomics is 4/10.

What is the revenue of Bionomics 2025?

The expected Bionomics revenue is 5.14 M AUD.

How high is the profit of Bionomics 2025?

The expected Bionomics profit is -436.87 M AUD.

What is the business model of Bionomics

The Australian company Bionomics Ltd is a biopharmaceutical company that was founded in 1998 and is headquartered in Adelaide. The company specializes in researching, developing, and marketing innovative therapies for neurological disorders, cancer, and metabolic diseases. Bionomics Ltd's business model includes two main divisions: the development of its own drugs and therapies, and collaboration with other pharmaceutical companies for joint drug development. One core competency of Bionomics Ltd is the research of peptide-based drugs. These drugs are derived from proteins and can be specifically used in the body to target certain cells or receptors. The company has filed several patents for peptide-based drugs and is currently developing promising drug candidates for cancer, depression, and anxiety disorders. Additionally, Bionomics Ltd has a strong expertise in drug research through the use of artificial intelligence (AI) and machine learning. The company uses these technologies to identify new drugs that target specific structures in the body, enabling more targeted and effective drug development. Bionomics Ltd also collaborates with other companies in the industry to facilitate the exchange of resources and expertise. The company has partnerships with various pharmaceutical companies and academic institutions to develop drugs together. This collaboration allows for a broader range of drugs and increased effectiveness, while also reducing development costs. Bionomics Ltd offers both its own drugs and drugs developed in collaboration with other companies. One promising product is the drug candidate "BNC210", which is being developed for the treatment of anxiety disorders. The drug has shown high efficacy and precision, making it a promising candidate in the market. Another promising product is "BNC101", a drug candidate for certain types of cancer that is currently being tested in Phase 2 studies. Overall, Bionomics Ltd has a flexible and diversified business model that allows the company to develop its own products and work with other companies. With its expertise in peptide-based drug research and the use of AI, the company is gaining importance in the industry. The portfolio of products and projects that the company is currently developing and bringing to market shows promising progress and makes Bionomics Ltd a company that will be successful in the long run.

What is the Bionomics dividend?

Bionomics pays a dividend of 0 AUD distributed over payouts per year.

How often does Bionomics pay dividends?

The dividend cannot currently be calculated for Bionomics or the company does not pay out a dividend.

What is the Bionomics ISIN?

The ISIN of Bionomics is AU000000BNO5.

What is the Bionomics WKN?

The WKN of Bionomics is 936199.

What is the Bionomics ticker?

The ticker of Bionomics is BNO.AX.

How much dividend does Bionomics pay?

Over the past 12 months, Bionomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionomics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Bionomics?

The current dividend yield of Bionomics is .

When does Bionomics pay dividends?

Bionomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bionomics?

Bionomics paid dividends every year for the past 0 years.

What is the dividend of Bionomics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bionomics located?

Bionomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bionomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bionomics from 2/14/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 2/14/2025.

When did Bionomics pay the last dividend?

The last dividend was paid out on 2/14/2025.

What was the dividend of Bionomics in the year 2024?

In the year 2024, Bionomics distributed 0 AUD as dividends.

In which currency does Bionomics pay out the dividend?

The dividends of Bionomics are distributed in AUD.

All fundamentals about Bionomics

Our stock analysis for Bionomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.